CEO David Kirn Uses 10b5‑1 Plan to Sell 1,922 Shares of 4D Molecular – A Sign of Insider Confidence, Not Panic.
Insider sale of 1,922 shares by 4D Molecular Therapeutics CEO under a 10b5‑1 plan shows cautious confidence, not a red flag.
- 4D MOLECULAR THERAPEUTICS IN
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read